Boston Scientific Corp.

Strong Financial Performance: Boston Scientific reported a 23% operational sales growth and 20% organic sales growth in Q4 2024, exceeding guidance expectations of 14%-16%. Full-year operational sales grew 18.5% and organic sales 16%, surpassing the anticipated 15%. Adjusted EPS also showed significant growth with Q4 EPS at $0.70 (up 26% YoY) and a full-year EPS of $2.51 (up 22% YoY).

2025 Outlook: For 2025, the company anticipates organic revenue growth of 10% to 12%, with a Q1 adjusted EPS guidance of $0.66 to $0.68. Overall, the full year adjusted EPS is projected between $2.80 and $2.87, indicating a growth of 12% to 14% compared to 2024. However, a foreign exchange headwind is expected to impact growth.

Market Expansion and Product Launches: Key drivers for future growth include the continued adoption of FerraPulse for atrial fibrillation treatment, which surpassed $1 billion in revenue in 2024, and strong performance in the Watchmen business, which is also projected to maintain around 20% growth. New product introductions such as Fairwave NAV and the Acura Prime Valve are expected to enhance market position.